Abe Alexander practices out of the New York office, where he focuses on securities fraud, corporate governance and shareholder rights litigation. 

As a principal member of the trial team prosecuting In re Merck Vioxx Securities Litigation, Abe helped recover over $1.06 billion on behalf of injured investors.  The case, which asserted claims arising out of the Defendants’ alleged misrepresentations concerning the safety profile of Merck's pain-killer, VIOXX, was settled shortly before trial and after more than 10 years of litigation, during which time plaintiffs achieved a unanimous and groundbreaking victory for investors at the U.S. Supreme Court. The settlement is the largest securities recovery ever achieved against a pharmaceutical company and among the 15 largest recoveries of all time.

Abe was also a principal member of the trial team that prosecuted In re Schering-Plough Corp./ENHANCE Securities Litigation and In re Merck & Co., Inc. Vytorin/Zetia Securities Litigation, which settled on the eve of trial for a combined $688 million.  This $688 million settlement represents the second largest securities class action recovery against a pharmaceutical company in history and is among the largest securities class action settlements of any kind.

Abe has also obtained several additional significant recoveries on behalf of investors in pharmaceutical and life sciences companies, including a $142 million recovery in Medina v. Clovis Oncology, Inc., a securities fraud class action arising from Defendants’ alleged misstatements about the efficacy and safety of its most important drug; a $77.5 million recovery in In re Myriad Genetics, Inc. Securities Litigation, a case arising from alleged misstatements concerning genetic testing products; a $55 million recovery in In re HeartWare International, Inc. Securities Litigation, a case arising from Defendants’ alleged misstatements about the device-maker’s compliance with FDA regulations and the performance of its key heart pump; a $44 million recovery in In re Adeptus Health Inc. Securities Litigation, a case arising from alleged misstatements concerning the liquidity and cash flow of the country's largest operator of freestanding emergency rooms; and a $39 million recovery, BioMarin Pharmaceutical Inc., a case arising from alleged misstatements concerning FDA review of a biologic. 

Abe secured a $450 million recovery in In re Kraft Heinz Securities Litigation, a case arising from alleged misstatements concerning the sustainability of Kraft Heinz’s cost-cutting measures and its brand investment and operations. Abe also secured a $149 million recovery on behalf of investors in Equifax, Inc., helping to lead a securities class action arising from one of the largest data breaches in American history. Abe also played a lead role in securing a $150 million settlement of investors’ claims against JPMorgan Chase arising from alleged misrepresentations concerning the trading activities of the so-called “London Whale,” and most recently, in securing a $95 million recovery on behalf of investors in Cognizant Technology Solutions dealing with alleged false statements and illegal payments to Indian governmental officials to secure favorable permits. 

He is currently prosecuting In re The Boeing Company Aircraft Securities LitigationHomyk v. ChemoCentryx, Inc.; and In re Seagate Tech. Holdings plc, among others.

Prior to joining the firm, Abe represented institutional clients in a number of high-profile securities, corporate governance, and antitrust matters.

Abe was an award-winning member of his law school's national moot court team. Following law school, Abe served as a judicial clerk to Chief Justice Michael L. Bender of the Colorado Supreme Court.

He was named a 2022 “Rising Star of the Plaintiff's Bar” by the National Law Journal, was named a 2021 "Rising Star" by Law360, and chosen by Benchmark ​Litigation for its “40 & Under Hot List.” Super Lawyers has also regularly selected Abe as a New York “Rising Star” in recognition of his accomplishments.